Cetuximab drug with chemo may cut death risk in lung cancer patients.Byline: ANI Washington, Sept 22 (ANI): Giving drug cetuximab (Erbitux) along with chemotherapy can significantly reduce death risk in lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. patients, researchers have found. The study showed that patients with advanced non-small cell lung cancer Lung Cancer, Non-Small Cell Definition Non-small cell lung cancer (NSCLC) is a disease in which the cells of the lung tissues grow uncontrollably and form tumors. Description There are two kinds of lung cancers, primary and secondary. who are given cetuximab (Erbitux) in addition to chemotherapy are 13pct less likely to die than those who receive chemotherapy alone, regardless of which chemotherapy drug cocktail Noun 1. drug cocktail - a combination of protease inhibitors taken with reverse transcriptase inhibitors; used in treating AIDS and HIV HAART, highly active antiretroviral therapy is used. The patients also experienced slower disease progression and an increased chance of tumour shrinkage. The researchers combined the data from four trials that investigated the addition of cetuximab to various different platinum-based chemotherapy combinations in first-line treatment A first-line treatment or first-line therapy is a medical therapy recommended for the initial treatment of a disease, sign or symptom, usually on the basis of empirical evidence for its efficacy. of advanced non-small cell lung cancer. "We found that patients who got cetuximab had a 13percent lower chance of dying within the three years of follow-up compared with those who got chemotherapy alone," said Professor Jean-Louis Pujol, chair of thoracic oncology at Montpelier Academic Hospital and professor of medicine at Montpelier University in France. "For lung cancer, considering that this disease is very resistant to treatment and that the prognosis is very poor, an improvement of that magnitude is meaningful. It's about the same as what you get from giving chemotherapy after surgery and that's accepted as standard treatment," the expert added. The median survival, a more crude measure of the drug's effect on death, was 9.4 months in the chemotherapy alone group and 10.3 months in the chemotherapy plus cetuximab group. The researchers also found 10pct improvement progression free survival, which measures the length of time a patient survives before the cancer gets worse. The study also found that patients who received the addition of cetuximab were 48pct more likely to experience tumour shrinkage. The findings were presented at Europe's largest cancer congress, ECCO An earlier Windows PIM from NetManage, Inc., Cupertino, CA (www.netmanage.com). ECCO provided a phone book, calendar, to-do list, outlining and notetaking. It was noted for its tightly integrated and sophisticated functions. 15 - ESMO ESMO European Society for Medical Oncology ESMO European Student Moon Orbiter ESMO Earth Science Mission Operations ESMO Excited-State Molecular Orbital 34. (ANI) Copyright 2009 Asian News International The Asian News International (ANI) agency provides multimedia news to China and 50 bureaus in India. It covers virtually all of South Asia since its foundation and presently claims, on its official website, to be the leading South Asia-wide news agency. (ANI) - All Rights Reserved. Provided by Syndigate.info an Albawaba.com company |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion